Investment
Features
FeesSafety
Academy
More
Pluang+

Compare British American Tobacco PLC (BTI) vs Crispr Therapeutics AG (CRSP) Price & Performance

British American Tobacco PLCTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

British American Tobacco PLC vs Crispr Therapeutics AG — how do they compare? British American Tobacco PLC trades at $56.92 (market cap $122.36B), while Crispr Therapeutics AG trades at $53.95 (market cap $5.23B). The key difference: British American Tobacco PLC is far larger — about 23.4× Crispr Therapeutics AG's market cap, and British American Tobacco PLC pays a 5.88% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

BTICRSP
Market Cap
$122.36B$5.23B
Sector
Consumer StaplesHealth
52-Week High
$66.70$76.78
52-Week Low
$50.39$44.34
Enterprise Value
$166.31B$3.65B
Dividend Yield
5.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

British American Tobacco PLC

BTI trades at $55.9, down 2.02% today, with a bearish technical signal overall despite bullish oscillators. The company reported Q2 2026 EPS of $2.25, beating expectations, and maintains strong profitability with a 24.99% net income margin. Recent news highlights its strategic tech partnership with ITC Infotech and workforce restructuring to cut costs.

Outlook is mixed: strong fundamentals and a 66.67% analyst buy rating support upside, but technical weakness and regulatory risks pose challenges. The stock offers value with a P/E of 14.48 and dividend yield, yet faces headwinds from declining combustibles and debt levels.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About British American Tobacco PLC

Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.

Read more on BTI

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP